UK health authority recommends Ebglyss for atopic dermatitis treatment in England

Key takeaways:

• The recommendation comes from the National Institute for Health and Care Excellence in the United Kingdom.
• Ebglyss (lebrikizumab) is an interleukin-13 inhibitor indicated for atopic dermatitis.

The National Institute for Health and Care Excellence has recommended Ebglyss for the treatment of moderate to severe atopic dermatitis in the National Health Service England, according to an Almirall press release.

Approved by the European Commission and the U.K. Medicines and Healthcare products Regulatory Agency in December 2023, Ebglyss (lebrikizumab, Almirall) is an interleukin-13 inhibitor indicated for the treatment of moderate to severe AD in adults and adolescents aged at least 12 years who are candidates for systemic therapy.

With approximately 5.2 million adults and 2.5 million children with atopic dermatitis in the U.K., the National Institute for Health and Care Excellence (NICE) recommendation helps a large proportion of patients suffering daily.

“The NICE recommendation for lebrikizumab for eligible people 12 years and over suffering with moderate to severe AD in England is testament to the benefits this treatment can bring to patients due to its demonstrated efficacy, with 4-weekly maintenance dosing and an acceptable safety profile,” Jorgen Damsbo, general manager at Almirall UK, said in the release. “This is well aligned with our company purpose to transform the patient’s world by helping them realize their hopes and dreams for a healthy life."